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FR-900098 is a potent chemotherapeutic agent for
the treatment ofmalaria. Here we report the heterolo-
gous production of this compound inEscherichia coli
by reconstructing the entire biosynthetic pathway
using a three-plasmid system. Based on this system,
whole-cell feeding assays in combinationwith in vitro
enzymatic activity assays reveal an unusual func-
tional role of nucleotide conjugation and lead to the
complete elucidation of the previously unassigned
late biosynthetic steps. These studies also suggest
a biosynthetic route to a second phosphonate antibi-
otic, FR-33289. A thorough understanding of the
FR-900098 biosynthetic pathway now opens possi-
bilities for metabolic engineering in E. coli to increase
production of the antimalarial antibiotic and combi-
natorial biosynthesis to generate novel derivatives
of FR-900098.
INTRODUCTION
Malaria remains one of the most common life-threatening infec-
tions in developing countries, with up to 500 million infections
and over 1 million deaths per year (Snow et al., 2005). Current
antimalarial treatments include chloroquine and sulfadoxin pyri-
methamine, but the rapid emergence of antibiotic-resistant
strains is rendering these current therapies futile, creating an
urgent need for new effective drugs (Ridley, 2002; Wiesner
et al., 2003). FR-900098 and fosmidomycin represent a new
class of antimalarial compounds. These compounds were first
isolated from Streptomyces rubellomurinus and Streptomyces
lavendulae, respectively (Okuhara et al., 1980a). Studies have
shown that these two compounds bind in the active site and
effectively inhibit 1-deoxy-D-xylulose 5-phosphate reductoiso-
merase (DXR), the first step in the nonmevalonate pathway for
isoprenoid biosynthesis (MacSweeney et al., 2005). Genomic
analyses indicate that the genes encoding the nonmevalonate
pathway are present in a wide variety of Gram-negative andChemistry & Biology 17,Gram-positive bacteria, plants, and the parasite causing the
most virulent form of malaria, Plasmodium falciparum (Boucher
and Doolittle, 2000; Lange et al., 2000). Mammals produce iso-
prenoids via the mevalonate pathway; therefore, FR-900098
and fosmidomycin should not be detrimental to humans (Beytia
and Porter, 1976). Both compounds are currently undergoing
clinical trials and have shown great promise as malaria treat-
ments (Borrmann et al., 2004, 2006). Earlier work revealed that
FR-900098 is twice more effective than fosmidomycin against
various strains of P. falciparum in vitro and the closely related
P. vinckei in mice (Jomaa et al., 1999). Progress has been
made in the development of chemical synthetic routes for fosmi-
domycin (Hemmi et al., 1982) and FR-900098 (Fokin et al., 2007;
Hemmi et al., 1982), but we chose to pursue a biological route for
a more cost-effective way to produce these antimalarial
compounds.
Heterologous production of FR-900098 in Streptomyces livid-
ans and a proposed biosynthetic pathway were reported by Eliot
et al. (2008). The first step involved in FR-900098 biosynthesis,
a phosphoenolpyruvate (PEP) mutase reaction catalyzed by
FrbD, is common in almost all other known phosphonate
biosyntheses. Currently, only three other complete phosphonate
biosynthetic pathways have been identified (2-aminoethyl-
phosphonate [Barry et al., 1988], fosfomycin [Hidaka et al.,
1995; Woodyer et al., 2006], and bialaphos [Blodgett et al.,
2005; Schwartz et al., 2004]), all of which have a common
second step. In all of these cases, an irreversible thiamine pyro-
phosphate-dependent decarboxylation of phosphonopyruvate
(PnPy) to form phosphonoacetaldehyde is required to provide
a sufficient thermodynamic driving force to overcome the
unfavorable equilibrium created by PEP mutase. However, the
FR-900098 biosynthetic cluster does not contain a PnPy decar-
boxylase. FrbC, a homocitrate synthase homolog, catalyzes the
formation of 2-phosphonomethylmalate, thus creating a novel
route for phosphonate biosynthesis (Eliot et al., 2008).
The subsequent steps parallel the tricarboxylic cycle, resulting
in the formation of 2-oxo-4-phosphonobutyrate, an analog of
a-ketoglutarate. The final steps were proposed based only on
sequence homology of the remaining genes, without any defini-
tive assignment of order or function. A complete understanding
of the FR-900098 pathway could provide significant insight into57–64, January 29, 2010 ª2010 Elsevier Ltd All rights reserved 57
Figure 1. Heterologous Production of FR-900098 in E. coli
(A) Scheme for the three-plasmid system in an FR-900098-producing strain.
Each gene is under transcriptional control by strong T7 promoters indicated
by arrows.
(B) Time course production of FR-900098 in E. coli. Error bars represent stan-
dard deviations.
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FR-900098 Biosynthesisthe biosynthesis of all phosphonates. More importantly, heterol-
ogous expression inside a more genetically tractable host would
act as a platform toward creating novel and potentially more
potent derivatives of FR-900098 and increasing production of
the antimalarial compound to industrially desirable levels. Here
we report the heterologous production of FR-900098 in E. coli
and the deciphering of the late steps in FR-900098 biosynthesis,
verified through whole-cell feeding experiments and in vitro
assays with purified enzymes.
RESULTS AND DISCUSSION
Heterologous Production of FR-900098 in E. coli
To achieve heterologous production of FR-900098 in E. coli,
each of the genes in the biosynthetic gene cluster were first
checked for soluble expression inside the new host. Each of
the 11 genes was cloned, expressed, and then analyzed by
SDS-PAGE and western blot. All of the proteins had high expres-
sion and showed clear overexpression bands in E. coli, except
for FrbE and DxrB, which demonstrated low levels of soluble
expression detected only by western blot analysis (data not
shown). To reconstitute the FR-900098 biosynthetic pathway
in E. coli, each of the 11 genes in the biosynthetic cluster was
cloned into a set of three compatible Duet expression vectors
(pETDuet, pRSFDuet, and pACYCDuet). Each individual gene
is under the transcriptional control of a strong T7 promoter
and expression is inducible by the addition of isopropyl-b-D-
thiogalactopyranoside (IPTG). The constructed plasmids were
transformed into the heterologous host E. coli to create the
production strain. The heterologous production of FR-900098
was confirmed using liquid chromatography/mass spectrometry
(LC-MS) analysis as described in Eliot et al. (2008).
Deletion analysis was utilized to determine which genes were
required for heterologous production of FR-900098. Different
strains of E. coli were created which lacked a single gene from
the pathway and each was tested for its ability to produce
the compound. The strain lacking dxrB grew very slowly
upon protein induction and, although the strain eventually
grew to saturation, it produced significantly lower amounts of
FR-900098. As mentioned earlier, the dxrB gene encodes
a homolog of 1-deoxy-D-xylulose-5-phosphate reductoisomer-
ase, the known target of the antibiotic. This provided evidence
for the necessary inclusion of the dxrB gene in the E. coli
FR-900098-producing strains as a means of resistance from
increasing concentrations of the compound. The genes frbI
and frbJ were not essential for FR-900098 production in
E. coli; the overexpression of these two proteins more than likely
results in the unnecessary consumption of cellular resources,
which results in lower FR-900098 production. The final produc-
tion strain (pETDuet-frbABCD, pRSFDuet-frbHFG, pACYCDuet-
frbE-dxrB) did not include frbI or frbJ, resulting in the highest
production of FR-900098, 6.3mg/L (Figure 1). To our knowledge,
this is the first known heterologous production of a phosphonate
antibiotic in E. coli.
Whole-Cell Feeding Studies
To identify possible intermediates in the late steps of FR-900098
biosynthesis, a series of whole-cell feeding experiments was
conducted. Resting cells of E. coli were fed with 2-amino-4-58 Chemistry & Biology 17, 57–64, January 29, 2010 ª2010 Elsevierphosphonobutyrate (2APn), a glutamate analog which is effi-
ciently taken up by E. coli and also shown to crossfeed into
S. lividans deletion mutants (data not shown). Culture superna-
tants were analyzed for possible phosphonate intermediates
using a coupled LC-MS approach. Cells expressing FrbH
were found to accumulate CMP-50-3-aminopropylphosphonate
(CMP-50-3APn), and cells expressing FrbH, FrbF, and FrbG
had detectable levels of CMP-50-N-acetyl-3-aminopropyl-
phosphonate (CMP-50-Ac3APn), CMP-50-FR-900098, and FR-
900098. Thus, these initial whole-cell feeding studies suggested
that cytidine-50-monophosphate (CMP) -conjugated phospho-
nate intermediates are present during the late steps of
FR-900098 biosynthesis. These studies also showed that FrbG
is an essential component in the late steps of FR-900098 biosyn-
thesis, as definitive assignment of the function of the enzyme
was never made (Eliot et al., 2008). It is also interesting to note
that 2-oxo-4-phosphonobutyrate was detected in samples
containing a negative control (empty vector), providing evidence
that a ubiquitous cellular transaminase is able to carry out the
transamination of 2OPn to form 2APn.
Bifunctional Activity of FrbH
The role of frbH was investigated after overexpression and puri-
fication of a histidine-tagged FrbH fusion from E. coli. Based on
sequence homology to other known PLP-dependent enzymes,
the protein was originally believed to catalyze the decarboxyl-
ation of 2APn to yield 3APn (Eliot et al., 2008). However, repeatedLtd All rights reserved
Figure 2. FrbH Reaction
(A) Proposed order of reaction where CMP attachment occurs before decarboxylation.
(B) HPLC analysis of the FrbH reaction product.
(C) MS/MS data of CMP-50-3APn.
(D) HPLC analysis of FrbH-K466A mutant, which should remove decarboxylase activity.
(E) HPLC analysis of FrbH-K38A mutant, which should remove nucleotide transferase activity.
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search of full-length FrbH revealed two distinct domains: a nucle-
otide transferase domain, followed by a PLP-dependent amino-
transferase/decarboxylase domain. Only the second domain
was originally believed to be active, but based on the whole-
cell feeding studies with 2APn, we began to investigate whether
FrbH is bifunctional (Figure 2A). An in vitro reaction mixture con-
taining both 2APn and cytidine-50-triphosphate (CTP) showed
nearly complete conversion of CTP to several compounds,
including CMP, cytidine-50-diphosphate (CDP), CMP-50-2APn,
and predominantly CMP-50-3APn (Figure 2B). LC-MS of the
products CMP-50-2APn and CMP-50-3APn revealed the masses
m/z 487 and 443, respectively (Figure 2C). Furthermore, frag-
mentation of these two products in negative mode showed theChemistry & Biology 17,characteristic fragment ion of m/z 322, indicating the CMP
moiety on both of these compounds. These results suggest
FrbH condenses 2APn and CTP to form CMP-50-2APn and
then decarboxylates CMP-50-2APn to yield CMP-50-3APn.
Single-point mutations were designed to eliminate the activity
of each of the individual domains of FrbH to verify the proposed
order of reaction. PLP-dependent enzymes are known to bind to
the cofactor with a conserved lysine residue. A sequence align-
ment with CobD from Salmonella typhimurium revealed the
PLP-binding motif and the lysine at position 466 (Brushaber
et al., 1998). A K466A mutant was constructed, expressed,
and purified which should be unable to bind the PLP and thus
perform the decarboxylation. A second mutant was designed
to disrupt nucleotide transferase activity of FrbH. A sequence57–64, January 29, 2010 ª2010 Elsevier Ltd All rights reserved 59
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for isoprenoid biosynthesis) from E. coli revealed a common
lysine residue (K38 in FrbH) that eliminated enzymatic activity
(Richard et al., 2004). Under the same in vitro reaction conditions
as thewild-type FrbH, the K466Amutant produced only CMP-50-
2APn (Figure 2D). Although unable to totally abolish nucleotide
transferase activity, the K38A mutant had a mostly unreacted
CTP peak with a small peak corresponding to CMP-50-3APn
(Figure 2E). These results are conclusive evidence for FrbH cata-
lyzing the CMP attachment to 2APn followed by decarboxyl-
ation, yielding CMP-50-3APn (Figure 2A).
N-Acetyltransferase Activity of FrbF and N-Hydroxylase
Activity of FrbG
To complete the biosynthesis of FR-900098, the amino group of
CMP-50-3APn requires both hydroxylation and acetylation. The
order and identity of the enzymes catalyzing these two steps
were never definitively assigned in the original pathway (Eliot
et al., 2008). FrbF has strong homology to known N-acetyltrans-
ferases, and it was originally believed that FrbJ may be involved
in the hydroxylation step. However, based on the results of the
whole-cell feeding assays and deletion studies described above,
FrbG, a FAD/NADPH-dependent monooxygenase, was now
thought to catalyze the hydroxylation step instead of FrbJ. The
whole-cell feeding studies also suggest the order of the two
steps as acetylation followed by hydroxylation, because CMP-
50-Ac3APn was seen and not N-hydroxy-3-aminopropylphosph-
onate (CMP-50-H3APn). Coupled in vitro reactions with FrbF and
FrbG also supported this order of reaction, as there was always
a CMP-50-Ac3APn peak present but little to no CMP-50-H3APn
monitored (Figures 3A and 3B). To determine the order of the
acetylation and hydroxylation steps, each of the potential
substrates was purified and kinetic parameters for FrbF and
FrbG were obtained.
Although CMP-50-Ac3APn was believed to be an intermediate
in the pathway instead of CMP-50-H3APn, no activity was
observed for FrbG toward this substrate. FrbF was able to
accept either of the two potential substrates, meaning CMP-50-
Ac3APn is actually a dead-end in the FR-900098 biosynthetic
pathway rather than a true intermediate (Table 1). Kinetic
analysis of these two enzymes indicated that FrbF and FrbG
compete for the same intermediate, CMP-50-3APn, as they
both prefer this compound compared to the alternative (CMP-
H3APn for FrbF and CMP-50-Ac3APn for FrbG). However, FrbG
has 2.3-fold lower KM for CMP-5
0-3APn in comparison to FrbF,
so the enzyme can effectively direct the flux away from the
dead end. The reason for observing CMP-50-Ac3APn rather
than CMP-50-H3APn throughout the feeding experiments is
due to the buildup of the dead-end intermediate CMP-50-
Ac3APn, whereas the true intermediate, CMP-50-H3APn, is pre-
vented from accumulating because it is further processed by
FrbF. These results demonstrate that the flux of the pathway
must go through N-hydroxylation by FrbG followed by N-acety-
lation by FrbF and subsequently the more electrophilic CMP-50-
H3APn intermediate.
Nucleotide Hydrolase Activity of FrbI
The last step in the biosynthesis of FR-900098was evident based
on the presence of the intermediate CMP-50-FR-900098.60 Chemistry & Biology 17, 57–64, January 29, 2010 ª2010 ElsevierRemoval of the CMP moiety from CMP-50-FR-900098 is neces-
sary in order to produce the final compound FR-900098. Nucleo-
tide hydrolases are known to catalyze the hydrolytic breakdown
of a wide variety of nucleotide derivatives (McLennan, 2006).
FrbI has high homology to this family of enzymes and could likely
catalyze the hydrolysis of CMP-50-FR-900098 to produce
FR-900098 and CMP. In order to perform in vitro enzymatic
studies, the enzyme FrbI was overexpressed in E. coli and puri-
fied to homogeneity. An in vitro reaction involving FrbI was tested
and found to produce a significant amount of FR-900098,
whereas only a very small amount of FR-900098 was present
in the absence of FrbI, likely due to the instability of CMP-50-
FR-900098 (Figures 3C and 3D). Thus, it is clear that FrbI cata-
lyzes the hydrolysis of CMP-50-FR-900098 to form FR-900098
and CMP. Interestingly, FrbI also catalyzed the hydrolysis of all
the other CMP-containing intermediates within the pathway
and even showed a small amount of activity toward CTP. This
is not surprising given that nucleotide hydrolases typically have
broad substrate specificity (Bessman et al., 1996). This promis-
cuous behavior is evident from the gene deletion analysis previ-
ously mentioned. The gene frbI is not required for FR-900098
biosynthesis in E. coli as a ubiquitous nucleotide hydrolase is
able to cleave the CMP, yielding the final compound FR-900098.
Monooxygenase Activity of FrbJ
FrbJ is homologous to a-ketoglutarate-dependent monooxyge-
nases capable of functionalizing an inactivated C-H bond.
Although not required for FR-900098 biosynthesis, we believed
the enzyme may be involved in the synthesis of another phos-
phonate antibiotic, FR-33289. Production of this compound
was observed in both the native S. rubellomurinus and heterolo-
gous S. lividans 4G7 host (data not shown). FR-33289 has similar
antibacterial properties compared to FR-900098 and could also
be another effective antimalarial compound (Okuhara et al.,
1980b). An in vitro reaction mixture containing active FrbJ was
able to convert FR-900098 to FR-33289 (Figures 3E and 3F).
Expression of frbJ along with the remaining genes in the pathway
could provide a means for production of FR-33289.
In summary, we have heterologously produced FR-900098 in
E. coli and demonstrated that the late steps of FR-900098
biosynthesis follow a series of novel intermediates (Figure 4).
Of special note, the nucleotide attachment to the intermediates
in FR-900098 biosynthesis seems to play an unprecedented
role. It is traditionally believed that attachment of the nucleotide
serves only as an activator for otherwise challenging chemistry in
natural product biosyntheses containing nucleotide-conjugated
intermediates. For example, in the biosynthesis of phosphino-
thricin tripeptide, PhpF catalyzes the condensation of CTP
with phosphonoformate to form CMP-50-phosphonoformate
(CMP-50-PF). This reaction was required so that the activated
intermediate would be primed for transfer of the phosphonofor-
mate group to the appropriate acceptor molecule (Blodgett
et al., 2007). As part of the nonmevalonate pathway, IspD has
been shown to catalyze the formation of 4-diphosphocytidyl-2-
C-methyl-D-erythritol (CDP-ME) from 2-C-methyl-D-erythritol
4-phosphate and CTP, which facilitates the subsequent forma-
tion of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (Rohdich
et al., 1999). However, in FR-900098 biosynthesis, nucleotide
attachment clearly does not activate the bond for subsequentLtd All rights reserved
Figure 3. FrbG, FrbF, FrbI, and FrbJ Reactions
(A) HPLC analysis of the FrbG and FrbF combined reaction product.
(B) MS/MS data of CMP-50-FR-900098.
(C) HPLC analysis of the FrbI reaction product.
(D) MS/MS data of FR-900098.
(E) HPLC analysis of the FrbJ reaction product.
(F) MS/MS data of FR-33289.
Chemistry & Biology
FR-900098 Biosynthesischemical reactions. Conjugation to CMP likely functions as a
recognition mechanism to help distinguish among other metab-
olites within the cell and, more importantly, as a requirement forChemistry & Biology 17,enzymatic activity. This hypothesis was substantiated by our
recent determination of the cocrystal structure of FrbG with the
cofactor NADPH (data not shown). Examination of this structure57–64, January 29, 2010 ª2010 Elsevier Ltd All rights reserved 61
Table 1. Kinetic Parameters for FrbF and FrbG Reactions with
Each of the Potential Substrates
Enzyme Substrate
kcat (min
1)
(Mean ± SD)
KM (mM)
(Mean ± SD)
kcat/KM
(mM1 min1)
FrbF CMP-50-3APn 3.46 ± 0.16 35.2 ± 3.2 98.0
CMP-50-H3APn 2.04 ± 0.43 52.3 ± 3.0 39.0
FrbG CMP-50-3APn 5.92 ± 0.38 15.1 ± 1.5 391
CMP-50-Ac3APn ND
ND, no detectable activity; SD, standard deviation.
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the active site. Thus, we proposed a novel reaction mechanism
for the N-hydroxylation catalyzed by FrbG. Briefly, the substrate
andNADPH cofactor compete for the same binding pocket in the
enzyme, and the nucleotide helps dock the substrate in the
correct position. The remaining enzymes in the pathway likely
evolved to accept substrates conjugated to CMP rather than
those proposed in the original pathway.
SIGNIFICANCE
We have successfully produced a potent antimalarial agent,
FR-900098, in a recombinant E. coli strain and elucidated
the biosynthetic mechanisms of the late steps involved
in FR-900098 biosynthesis. Notably, a nucleotide CMP is
conjugated to several of the intermediates, which seemsFigure 4. Revised FR-900098 Pathway
Each of the final steps in the FR-900098 biosynthetic pathway has been dem
biosynthetic pathway are as follows: I, phosphoenolpyruvate; II, phosphono
2-oxo-4-phosphonobutyrate; VI, 2-amino-4-phosphonobutyrate; VII, CMP-50-3
nate; IX, CMP-50-FR-900098.
62 Chemistry & Biology 17, 57–64, January 29, 2010 ª2010 Elsevierto play an unprecedented role in natural product biosyn-
thesis. Instead of activating a chemical bond, the nucleotide
conjugation seems to serve as a substrate recognition
mechanism. In addition, a biosynthetic route to a second
phosphonic acid antibiotic, FR-33289, was discovered,
which is embedded in the biosynthetic route to FR-900098,
and its production is regulated by a single enzyme, FrbJ.
This compound could also be effective in the treatment of
malaria. These studies now open possibilities for metabolic
engineering in E. coli to increase production of the antima-
larial antibiotic and combinatorial biosynthesis to generate
novel derivatives of FR-900098withmore potent antimalarial
activity.EXPERIMENTAL PROCEDURES
Heterologous Production of FR-900098 in E. coli
An overnight culture of the production strain (pETDuet-frbABCD, pRSFDuet-
frbHFG, pACYCDuet-frbE-dxrB in E. coli BL21[DE3] cells) was grown
at 37C in Luria-Bertani (LB) medium broth using the following antibiotic
concentrations: 50 mg/ml ampicillin, 25 mg/ml kanamycin, and 12.5 mg/ml
chloramphenicol. The cultures were diluted 1:100 in fresh medium and grown
at 37C to an OD600 of 0.7. At that point, the expression of the recombinant
genes was induced with 0.3 mM IPTG and the culture was incubated at 30C
with shaking (250 rpm). Samples (1 ml) were then removed from the cultures at
specific time points and stored at 80C. Frozen samples were thawed at
room temperature and centrifuged at maximum speed for 2 min. Supernatants
from the samples were then analyzed by LC-MS to determine the concentra-
tion of FR-900098.onstrated in vitro using purified enzymes. Intermediates in the FR-900098
pyruvate; III, 2-phosphonomethylmalate; IV, 3-phosphonomethylmalate; V,
-aminopropylphosphonate; VIII, CMP-50-N-hydroxy-3-aminopropylphospho-
Ltd All rights reserved
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E. coli BL21(DE3) cells expressing empty vector (control) and FrbH and cells
overexpressing FrbH, FrbF, FrbG, and DxrB were cultured overnight at 37C
in Terrific Broth mediumwith appropriate antibiotics. The cultures were diluted
1:100 in fresh medium and grown at 37C to an OD600 of0.7. Protein expres-
sion was induced by the addition of 0.3 mM IPTG final concentration and
cultures were grown at 25C for 24 hr. Cultures were then centrifuged at
3200 xg for 15 min and the supernatant was discarded. The cell pellet was re-
suspended in 1 ml of 10 mM Tris-HCl buffer (pH 7.0). Resuspended cells were
mixed with 20 mM final concentration (±)-2-amino-4-phosphonobutyrate
(2APn) and incubated at 30C for 24 hr. Samples were lysed by freeze/thaw
and centrifuged at maximum speed in amicrocentrifuge for 10min. The super-
natant (1 ml) was mixed with 9 ml of methanol, vortexed, and centrifuged at
3200 xg for 15 min. The pellet was discarded and the supernatant was rotary
evaporated down to a volume of 1ml. Samples were placed in a80C freezer
until analyzed by LC-MS using a 7 Tesla LTQ-FT mass spectrometer (Thermo
Finnigan, San Jose, CA, USA).Cloning, Expression, and Purification
The cloning of genes frbH, frbF, frbG, frbI, and frbJ from fosmid 4G7 was
similar to that in Eliot et al. (2008). Briefly, the genes were PCR amplified
with NdeI and HindIII sites and cloned into corresponding sites of pET28a,
designed to create an N-terminal histidine tag and transformed BL21(DE3)
cells. The cells were grown in LB medium supplemented with kanamycin
(50 mg/ml) at 37C to OD600 0.7 and then induced at 25C by the addition
of IPTG to a final concentration of 0.3 mM. During the purification of FrbH,
PLP was added to the media for a final concentration of 50 mg/ml. After
6–8 hr, the cells were harvested by centrifugation and resuspended in
20 mM Tris-HCl (pH 7.65), 15% glycerol, and 0.5 M NaCl at 4C. The
sample was freeze-thawed and then lysed further by sonication. After cellular
debris was removed by centrifugation, the N-His6-tagged proteins were
purified using immobilized metal-affinity chromatography with TALON Super-
flow Co2+ resin coupled to fast-performance liquid chromatography. The
purified protein was washed three times with 50 mM HEPES-Na+ buffer
and concentrated a final time. Concentrated protein was stored in 20% glyc-
erol at 80C.FrbH Activity
Wild-type and mutant FrbH activity was assayed by HPLC and LC-MS. The
assay mixture (100 ml) contained 2 mM (±)-2-amino-4-phosphonobutyric
acid, 1 mM CTP, 10 mM MgCl2, and His6-FrbH in 50 mM HEPES-Na
+ buffer
at pH 7.25. The reaction was initiated with the addition of 25 mg of purified
wild-type or mutant FrbH and incubated at 30C for 2 hr. Reaction mixtures
were transferred into Microcon centrifugal filter devices (MWCO 10,000) and
centrifuged for 15 min at maximum speed. The reactions were then analyzed
by LC-MS.FrbG and FrbF Activity
The activity of FrbG and FrbF was demonstrated in a coupled assay with FrbH.
The assay mixture (100 ml) contained 2 mM (±)-2-amino-4-phosphonobutyric
acid, 1 mM CTP, 10 mM MgCl2, 1 mM AcCoA, 1 mM NADPH, His6-FrbH,
His6-FrbF, and His6-FrbG in 50 mM HEPES-Na
+ buffer (pH 7.25). The reaction
was initiated with the addition of 25 mg of purified FrbF and 35 mg of purified
FrbG. Reaction mixtures were transferred into Microcon centrifugal filter
devices (MWCO 10,000) and centrifuged for 15 min at maximum speed. The
reactions were then analyzed by LC-MS.FrbI Activity
The activity of FrbI was demonstrated in a coupled assay with FrbH, FrbF,
and FrbG. The assaymixture (100 ml) contained 2mM (±)-2-amino-4-phospho-
nobutyric acid, 1 mM CTP, 10 mM MgCl2, 1 mM AcCoA, 1 mM NADPH,
His6-FrbH, His6-FrbF, His6-FrbG, and His6-FrbI in 50 mM HEPES-Na
+ buffer
(pH 7.25). The reaction was initiated with the addition of 25 mg of purified
FrbI and incubated at 30C for 2 hr. Reaction mixtures were transferred
into Microcon centrifugal filter devices (MWCO 10,000) and centrifuged for
15 min at maximum speed. The reactions were then analyzed by LC-MS.Chemistry & Biology 17,FrbJ Activity
FrbJ activity was assayed by HPLC and LC-MS. The assay mixture (100 ml)
contained 1mMFR-900098, 1mM a-ketoglutarate, 1mMFeSO4, 4mMascor-
bic acid, and His6-FrbJ in 50 mM HEPES-Na
+ buffer (pH 7.25). The reaction
was initiated with the addition of 25 mg of purified FrbJ and incubated at
25C for 4 hr. Reaction mixtures were transferred into Microcon centrifugal
filter devices (MWCO 10,000) and centrifuged for 15 min at maximum speed.
The reactions were then analyzed by LC-MS.
LC-MS Analysis of CMP-Containing Compounds
Products of the enzymatic reactions were analyzed by an Agilent 1100 series
LC/MSD XCT plus-ion-trapmass spectrometer (Agilent, Palo Alto, CA, USA) at
the Roy J. Carver Metabolomics Center at the University of Illinois (Urbana, IL,
USA). The liquid chromatography was performed using an Agilent 1100 series
HPLC equipped with an online degasser, binary pump, and autosampler.
Analytes were resolved on a 150 3 4.6 mm Agilent C18 reverse-phase HPLC
column. HPLC parameters were as follows: 25C; solvent A: 15 mM ammo-
nium formate; solvent B: 20 mM ammonium acetate; gradient: 25% B at
0 min, then to 100% B in 10 min, and finally maintain 100% B for 3 min; flow
rate: 0.3 ml/min; detection by UV absorbance at 254 nm. The mass spectrom-
etry was performed using an Agilent XCT ion-trap MSD mass spectrometer.
Mass spectra were acquired in ultrascan mode using electrospray ionization
(ESI) with negative polarity. The MS system was operated using a drying
temperature of 350C, a nebulizer pressure of 35 psi, a drying gas flow of
8.5 L/min, and a capillary voltage of 4500 V.
LC-MS Analysis of FR-900098 and FR-33289
LC-MS was performed using an Agilent 1100 series LC/MSD XCT plus-ion-
trap mass spectrometer. The liquid chromatography was performed using
an Agilent 1100 series HPLC equipped with an online degasser, binary
pump, and autosampler. The mobile phase contained 0.1% formic acid in
ddH2O (solvent A) and 100% acetonitrile (solvent B). Analytes were resolved
on a 1003 4.6mmSynergi 4u Fusion-RP 80A analytical column (Phenomenex,
Torrance, CA, USA) at a flow rate of 200 ml/min with a gradient of 0%–40%
solvent B for 10 min, a gradient of 40%–100% solvent B for 3 min, and
100% solvent B for 5 min. The mass spectrometry was performed using an
Agilent XCT ion-trap MSD mass spectrometer. Mass spectra were acquired
in ultrascan mode using ESI with positive polarity. The system was operated
using a drying temperature of 350C, a nebulizer pressure of 35 psi, a drying
gas flow of 8.5 L/min, and a capillary voltage of 4500 V. For determination of
titers, extracted ion chromatograms were generated from suitable ions of
each analyte, and the integrated areas corresponding to each compound
were compared to standards. Fosmidomycin was used as an internal standard
to measure FR-900098 concentrations.
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